Avicanna (AVCN) Q3 2025 earnings summary

Executive summary

• Achieved consecutive quarters of revenue growth in Canada, driven by medical affairs initiatives and increased engagement with the medical community.

• Expanded global collaborations and intellectual property portfolio, including a new US patent for topical cannabinoid compositions.

• Continued international expansion with first export of organic certified CBD flower to Switzerland and launch of re+PLAY CBD wellness brand in the US.

Financial highlights

• Q3 2025 revenue reached $6.40 million, with $18.88 million for the nine-month period ended September 30, 2025.

• Canadian revenue increased by 4% sequentially, and international revenue rose by approximately 6% from Q2 2025.

• Gross profit was $3.15 million for Q3, with a gross margin of 49%, down from 57% in the prior year due to non-recurring costs and one-time adjustments.

• Adjusted EBITDA loss of $0.79 million for Q3, with a nine-month adjusted EBITDA loss of $0.61 million, showing improvement over the prior year.

Outlook and guidance

• Management remains confident in the path toward sustainable profitability, focusing on disciplined execution and long-term value creation.

• Forward-looking statements highlight expectations for continued business growth and expansion of product offerings.